open access

Vol 11, Supp. H (2015)
Case report
Published online: 2015-12-18
Get Citation

A response to the ipilimumab treatment of a patient with a diagnosis of metastatic melanoma

Anika Pękala, Małgorzata Ułańska, Maria Błasińska-Morawiec

open access

Vol 11, Supp. H (2015)
CASE REPORT
Published online: 2015-12-18

Abstract

In the past years there has been a great progress in the treatment of advanced melanoma. Melanoma patients with distant metastases are still characterized by poor outcomes. Immunotherapeutic oncology gives a chance of long-term survival for patients with metastatic melanoma by engaging the strength of the immune system to fight the tumor cells. One of the drugs giving great hope in the treatment of advanced melanoma is ipilimumab. Randomized clinical trials demonstrated that the use of ipilimumab significantly prolongs overall survival of melanoma patients after the failure of previous systemic therapy. Although we need to remember that the clinical benefit of treatment with anti-CTLA-4 can only benefit a part of patients. Due to different kinetic responses to immunotherapy ipilimumab, it is important to assess the response to treatment carried out by modified immunological criteria (irRC). We describe the case of a 68-old year woman with a diagnosis of metastatic melanoma, in which the use of ipilimumab resulted in a long-term clinical benefit.

Abstract

In the past years there has been a great progress in the treatment of advanced melanoma. Melanoma patients with distant metastases are still characterized by poor outcomes. Immunotherapeutic oncology gives a chance of long-term survival for patients with metastatic melanoma by engaging the strength of the immune system to fight the tumor cells. One of the drugs giving great hope in the treatment of advanced melanoma is ipilimumab. Randomized clinical trials demonstrated that the use of ipilimumab significantly prolongs overall survival of melanoma patients after the failure of previous systemic therapy. Although we need to remember that the clinical benefit of treatment with anti-CTLA-4 can only benefit a part of patients. Due to different kinetic responses to immunotherapy ipilimumab, it is important to assess the response to treatment carried out by modified immunological criteria (irRC). We describe the case of a 68-old year woman with a diagnosis of metastatic melanoma, in which the use of ipilimumab resulted in a long-term clinical benefit.

Get Citation

Keywords

melanoma, ipilimumab, treatment, immunotherapy

About this article
Title

A response to the ipilimumab treatment of a patient with a diagnosis of metastatic melanoma

Journal

Oncology in Clinical Practice

Issue

Vol 11, Supp. H (2015)

Article type

Case report

Pages

1-6

Published online

2015-12-18

Keywords

melanoma
ipilimumab
treatment
immunotherapy

Authors

Anika Pękala
Małgorzata Ułańska
Maria Błasińska-Morawiec

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl